A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

Study acronym: ADsolve
StatusCompleted
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 4 more changesShow less
    • Study completion date changed from estimate of Sep 2026 to Sep 21, 2026
    • Eligibility criteria expanded, about 27 words
    • Secondary endpoints: details revised at 2 of 11 entries
    • Site details revised at 4 of 66 sites
  2. Trial status changed: Recruiting → Active, Not Recruiting
    • Enrollment increased: 200 → 233 participants
    • Primary completion pushed from Apr 2026 to May 14, 2026
    • Site details revised at 66 of 66 sites
    v16
  3. Trial sites reduced: 71 → 66 locationsv15
  4. Study sites: 73 to 71v14
  5. Study sites revised (73)v13
Show 11 earlier versionsHide 11 earlier versions
  1. Study sites revised (73)v12
  2. Study sites: 74 to 73v11
  3. Site details revised at 2 of 74 sitesv10
  4. Site details revised at 9 of 74 sitesv9
  5. Site contacts updated at 1 of 74 sitesv8
  6. Site contacts updated at 1 of 74 sitesv7
  7. Site details revised at 1 of 74 sitesv6
  8. Site details revised at 7 of 74 sitesv5
  9. Study sites: 75 to 74v4
  10. Study sites revised (75)v3
  11. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 44 to 75
    • Start date changed from estimate of Jun 2025 to Jun 16, 2025
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Atopic Dermatitis
500 trials monitored
See 18 trials at risk
The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.
Trial Details
NCT Number NCT07006792
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Atopic Dermatitis
Related terms Dermatitis, Atopic
Enrollment 233 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov